• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy.

作者信息

Wudhikarn Kitsada, Padrnos Leslie, Lasho Terra, LaPlant Betsy, Kumar Shaji, Dispenzieri Angela, Lacy Martha, Rajkumar S Vincent, Gertz Morie, Mangaonkar Abhishek A, Gonsalves Wilson, Ketterling Rhett, Shi Chang-Xin, Fonseca Rafael, Stewart A Keith, Patnaik Mrinal M

机构信息

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

Division of Hematology-Oncology, Mayo Clinic, Phoenix, Arizona.

出版信息

Am J Hematol. 2021 May 1;96(5):E157-E162. doi: 10.1002/ajh.26125. Epub 2021 Feb 23.

DOI:10.1002/ajh.26125
PMID:33580975
Abstract
摘要

相似文献

1
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy.接受自体干细胞移植后来那度胺维持治疗的多发性骨髓瘤患者中克隆性造血的临床相关性及预后影响
Am J Hematol. 2021 May 1;96(5):E157-E162. doi: 10.1002/ajh.26125. Epub 2021 Feb 23.
2
Melphalan-based autologous transplant in octogenarian multiple myeloma patients.基于美法仑的自体移植用于八旬多发性骨髓瘤患者。
Am J Hematol. 2019 Jan;94(1):E2-E5. doi: 10.1002/ajh.25310. Epub 2018 Oct 31.
3
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.多发性骨髓瘤自体移植后，来那度胺维持治疗持续时间延长可带来更长生存期。
Leuk Lymphoma. 2019 Feb;60(2):511-514. doi: 10.1080/10428194.2018.1473577. Epub 2019 Jan 8.
4
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
5
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.来那度胺维持治疗在非清髓性异基因造血干细胞移植治疗多发性骨髓瘤中不可行：HOVON 76 试验结果。
Blood. 2011 Sep 1;118(9):2413-9. doi: 10.1182/blood-2011-04-348292. Epub 2011 Jun 20.
6
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.德国骨髓瘤多中心组（GMMG）试验 HD6 的原理和设计：一项关于在新诊断骨髓瘤患者中 VRD 诱导/巩固和来那度胺维持中使用埃罗妥珠单抗的影响的随机 III 期试验。
BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.
7
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.老年多发性骨髓瘤患者管理的最新观点：关注来那度胺。
Clin Interv Aging. 2020 May 4;15:619-633. doi: 10.2147/CIA.S196087. eCollection 2020.
8
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.来那度胺与硼替佐米维持治疗多发性骨髓瘤自体造血干细胞移植后的选择。
Bone Marrow Transplant. 2018 Jun;53(6):701-707. doi: 10.1038/s41409-018-0177-6. Epub 2018 Apr 27.
9
Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.移植后雷那度胺维持治疗新诊断多发性骨髓瘤：真实世界的结局和成本。
Future Oncol. 2019 Dec;15(35):4045-4056. doi: 10.2217/fon-2019-0422. Epub 2019 Oct 18.
10
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.来那度胺联合化疗与自体移植，随后来那度胺联合泼尼松与来那度胺维持治疗多发性骨髓瘤患者：一项随机、多中心、3 期试验。
Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.

引用本文的文献

1
Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma.多发性骨髓瘤患者造血细胞中的嵌合染色体改变与临床结局。
Leukemia. 2024 Nov;38(11):2456-2465. doi: 10.1038/s41375-024-02396-3. Epub 2024 Sep 2.
2
Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis.供者嵌合性造血在异基因和自体造血干细胞移植中的作用：系统评价和荟萃分析。
Bone Marrow Transplant. 2024 Nov;59(11):1585-1593. doi: 10.1038/s41409-024-02403-2. Epub 2024 Aug 25.
3
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, meta-analysis, and call to action.
造血细胞移植中克隆性造血的临床影响：综述、荟萃分析及行动呼吁
Haematologica. 2024 Dec 1;109(12):3952-3964. doi: 10.3324/haematol.2024.285392.
4
Epigenetic roles in clonal hematopoiesis and aging kidney-related chronic kidney disease.表观遗传学在克隆性造血和衰老相关慢性肾脏病中的作用。
Front Cell Dev Biol. 2023 Oct 20;11:1281850. doi: 10.3389/fcell.2023.1281850. eCollection 2023.
5
Understanding DNA Damage Response and DNA Repair in Multiple Myeloma.了解多发性骨髓瘤中的DNA损伤反应与DNA修复
Cancers (Basel). 2023 Aug 17;15(16):4155. doi: 10.3390/cancers15164155.
6
Clonal hematopoiesis with and mutations impairs regeneration in autologous stem cell transplant recipients.携带 和 突变的克隆性造血会损害自体干细胞移植受者的再生。
Haematologica. 2023 Dec 1;108(12):3308-3320. doi: 10.3324/haematol.2023.282992.
7
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.克隆性造血与基于来那度胺的套细胞淋巴瘤治疗期间的血液学毒性相关。
Leukemia. 2022 Dec;36(12):2912-2916. doi: 10.1038/s41375-022-01725-8. Epub 2022 Oct 23.
8
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms.浆细胞肿瘤患者中，不确定潜能克隆性造血（CHIP）的分布与种族无关。
Blood Cancer J. 2022 Jul 26;12(7):112. doi: 10.1038/s41408-022-00706-5.
9
Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis.克隆性造血突变与临床结局的关联：系统评价和荟萃分析。
Am J Hematol. 2022 Apr;97(4):411-420. doi: 10.1002/ajh.26465. Epub 2022 Jan 19.